Major Landmark Fluid Resuscitation Trials
The most critical landmark trials in fluid resuscitation are SAFE (2004), ALBIOS (2014), SMART (2018), and CHEST (2012), with current evidence strongly favoring balanced crystalloids over saline and showing no mortality benefit for albumin or colloids in septic shock.
Key Landmark Trials and Their Findings
SAFE Study (2004) - The Albumin Question
The SAFE trial enrolled nearly 7,000 critically ill patients comparing 4% albumin to 0.9% saline for resuscitation 1. The trial showed no mortality difference between albumin and saline in the overall population, though post-hoc analysis suggested potential benefit in septic shock subgroups (OR 0.71,95% CI 0.52-0.97) 1. Importantly, the albumin group required significantly less total fluid volume (3011 mL vs 3522 mL, p<0.001) 1.
ALBIOS Study (2014) - High-Dose Albumin
This trial evaluated 20% albumin in septic patients targeting elevated serum albumin levels 1. The study found no mortality benefit (OR 1.00,95% CI 0.87-1.14), though it did show improved cardiovascular SOFA scores and shorter vasopressor duration 1. The observed mortality (30%) was substantially lower than predicted (45%), limiting the study's power 1.
CRISTAL Study - Colloids vs Crystalloids
CRISTAL compared colloids (including gelatins in 304/774 patients) to crystalloids in patients with mainly septic shock 1. No mortality benefit was demonstrated for colloids, and subsequent meta-analyses confirmed non-superiority of gelatins, with one showing higher anaphylactic reaction rates 1.
SMART Study (2018) - Balanced Crystalloids vs Saline
In the sepsis subgroup of 2,336 patients, balanced crystalloids reduced major adverse kidney events compared to isotonic saline (OR 0.80,95% CI 0.67-0.94) with a trend toward lower in-hospital mortality (OR 0.80,95% CI 0.67-0.97) 1. Post-hoc analysis by Brown et al. in medical ICU patients receiving higher fluid volumes showed reduced 30-day mortality and composite renal events (OR 0.74,95% CI 0.59-0.93) 1.
CHEST Trial (2012) - Hydroxyethyl Starch
This large trial comparing 6% HES 130/0.4 to saline in 7,000 critically ill patients was designed to assess 90-day mortality and renal injury 2. The trial contributed to evidence against routine HES use.
Current Guideline Recommendations
Balanced Crystalloids Over Saline (GRADE 2+)
In patients with sepsis or septic shock, use balanced crystalloids rather than 0.9% NaCl for fluid resuscitation to reduce mortality and adverse renal events 1. This recommendation is based on the SMART trial findings and subsequent analyses showing consistent benefit in the septic population.
Albumin Not Recommended as First-Line (GRADE 2-)
Compared to crystalloids, albumin is probably not recommended as first-line treatment in sepsis or septic shock to reduce mortality or renal replacement therapy requirement 1. Despite six meta-analyses, only one (Xu et al.) found 90-day mortality benefit in septic shock (OR 0.81,95% CI 0.67-0.97) 1. Five other meta-analyses found no benefit for either 4-5% or 20% albumin 1.
No Recommendation for Second-Line Albumin
Experts could not issue a recommendation for albumin as second-line treatment in patients with major hypoalbuminemia or requiring large fluid volumes, despite evidence of improved circulatory function and lower fluid requirements 1.
Emerging Evidence on Fluid Restriction
CLASSIC Trial (2016)
This Scandinavian feasibility trial randomized 151 septic shock patients to fluid restriction versus standard care after initial resuscitation 3. The restriction protocol successfully reduced resuscitation fluid volumes by 1.2L at day 5 (p<0.001), with exploratory outcomes pointing toward benefit: fewer ischemic events (3/75 vs 9/76), less worsening of acute kidney injury (27/73 vs 39/72, OR 0.46, p=0.03), and lower 90-day mortality (25/75 vs 31/76) 3.
RIFTS Trial (2019)
This pilot study of 109 patients compared restrictive resuscitation (≤60 mL/kg) to usual care over 72 hours 4. The restrictive group received significantly less fluid (47.1 vs 61.1 mL/kg, p=0.01) with no increase in 30-day mortality (21.8% vs 22.2%), organ failure, or adverse events 4.
REFRESH Trial (2018)
Among 99 ED patients with suspected sepsis and hypotension, restricted fluids with early vasopressor resulted in median 2387 mL versus 3000 mL in usual care (p<0.001) 5. Mortality at 90 days was similar (8% vs 6%) with no increase in serious adverse events 5.
Recent Network Meta-Analysis (2025)
A comprehensive network meta-analysis of 28 RCTs encompassing 8,770 patients provides the most current synthesis 6. Balanced crystalloids demonstrated superior efficacy over low molecular weight HES (RR 0.84,95% CrI 0.75-0.95) and saline (RR 0.89,95% CrI 0.81-0.97) in reducing 90-day mortality 6. Balanced crystalloids ranked highest for reducing 28-day mortality (SUCRA=71.4%), RRT requirement (SUCRA=75.5%), and 90-day mortality (SUCRA=86.3%) 6. Hyperoncotic albumin was most effective for preventing acute kidney injury (SUCRA=74.5%) 6.
Critical Pitfalls and Caveats
Common pitfall: The FEAST trial (2013) in African children with severe febrile illness showed that rapid fluid boluses increased 48-hour mortality by 3.3% compared to no bolus 7. Excess deaths were primarily from cardiovascular collapse rather than fluid overload 7. While this pediatric population differs from adult sepsis, it challenges assumptions about aggressive early resuscitation.
Albumin controversy: Despite theoretical benefits (anti-inflammatory, antioxidant properties, volume expansion), no high-quality study has demonstrated survival benefit 1. The CRYCO observational study suggested potential renal harm with 20% albumin, though RCTs have not confirmed this risk 1.
HES avoidance: Multiple trials and meta-analyses have established that hydroxyethyl starch offers no benefit and may cause renal injury, leading to its abandonment in septic shock 2.